Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immun...
Replimune Group (NASDAQ:REPL) reported quarterly losses of $(0.90) per share which missed the analyst consensus estimate of $(0...
BMO Capital analyst Evan David Seigerman upgrades Replimune Group (NASDAQ:REPL) from Underperform to Market Perform and rais...
HC Wainwright & Co. analyst Robert Burns upgrades Replimune Group (NASDAQ:REPL) from Neutral to Buy and announces $12 pr...
JP Morgan analyst Anupam Rama upgrades Replimune Group (NASDAQ:REPL) from Underweight to Neutral and announces $11 price tar...
Shares of Replimune Group are rising Monday after the clinical stage biotechnology company shared an important regulatory update.
